Page 36 - Dan Budwick News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Relay Therapeutics Expands Clinical Leadership Team with Addition of Tara O’Meara and Charles Ferté Ms. O’Meara and Dr. Ferté bring extensive experience in drug development across oncology and genetic disease May 03, 2021 06:00 ET | Source: Relay Therapeutics, Inc. Relay Therapeutics, Inc. CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, today announced the appoint...

Relay Therapeutics Expands Clinical Leadership Team with Addition of Tara O’Meara and Charles Ferté - read this article along with other careers information, tips and advice on BioSpace

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Relay Therapeutics Extends Leadership in Integrating Computational and Experimental Approaches ... Relay Therapeutics, Inc.April 16, 2021 GMT Relay Therapeutics’ leadership in this new breed of biotech positions the company as  a strategic partner of choice for emerging technologies and founders in these fields ZebiAI amplifies Relay Therapeutics’ Dynamo™ platform with a library of industry-leading experimental DEL data sets and validated machine learning models deployed in hit finding and op...

Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021 March 15, 2021 08:00 ET | Source: Ovid Therapeutics Inc. Ovid Therapeutics Inc. New York, New York, UNITED STATES Announced signing of transaction transferring Ovid’s 50% of global rights to develop and commercialize soticlestat (TAK-935/OV935) to Takeda, under which Ovid is eligible to receive up to $856 million in payments, including an upfront payment of $196 million at closing Two pivotal Phase 3 trials of soticlestat in Dravet syn...

Press release content from Business Wire. The AP news staff was not involved in its creation. Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform March 12, 2021 GMT BOSTON--(BUSINESS WIRE)--Mar 12, 2021-- Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, announced today the closing of a $95 million Series C financing. The proceeds will be used to advance its lead development candidate into the clinic, accelerate pipeline growth...